To date, there are few reliable markers available to accurately predict prognosis of CRC, some molecular markers are in use for treatment decisions and patient stratification, such as the mutation status of BRAF V600E, NRAS and KRAS,24, 25, 26 that still have many insufficiency. Here, KRAS is linked to colorectal carcinoma.